Humana Inc vs Boston Beer Company Inc — how do they compare? Humana Inc trades at $445.06 (market cap $46.49B), while Boston Beer Company Inc trades at $171.2 (market cap $1.76B). The key difference: Humana Inc is far larger — about 26.4× Boston Beer Company Inc's market cap, and Humana Inc pays a 0.91% dividend while Boston Beer Company Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Humana Inc for 53 Days and Boston Beer Company Inc for 59 Days on average.
| HUM | SAM | |
|---|---|---|
Market Cap | $46.49B | $1.76B |
Volume | 2,567,704 | 264,496 |
Sector | Health | Consumer Staples |
52-Week High | $409.85 | $260.05 |
52-Week Low | $163.67 | $161.08 |
Typical Hold Time | 53 Days | 59 Days |
Enterprise Value | $53.84B | $1.53B |
Dividend Yield | 0.91% | — |
Signals from Pluang's Aura AI — not financial advice
Humana (HUM) trades at $396.51, down 1.92% on the day, with strong technical momentum showing bullish moving averages and key support at $391. The company demonstrates consistent revenue growth reaching $129.7B in 2025, though net margins have compressed to 0.88%. Recent quarterly earnings have exceeded expectations, with Q2 2026 EPS of $7.61 beating estimates of $7.27. Analyst sentiment remains positive with a $432.63 consensus price target representing 9% upside potential from current levels.
The investment case centers on Humana's dominant Medicare Advantage position and consistent revenue growth, though margin pressure and regulatory scrutiny present headwinds. With 43% of analysts maintaining buy ratings and institutional accumulation continuing, the stock offers exposure to healthcare demographics but requires monitoring of enrollment trends and cost management execution.
SAM trades at $168.16, down 1.3% over the past day, with a neutral technical signal and bearish moving averages. The stock has a P/E of 22.66 and P/S of 0.94, indicating moderate valuation. Recent earnings missed expectations in Q1 and Q2 2026, but net income improved to $108.47M in 2025. The company is expanding its product portfolio with new cocktails and coolers, though volume growth remains a challenge.
The outlook is mixed: analyst consensus is a $204.44 price target with a majority hold rating, but negative net income margin and ROE highlight profitability risks. Key opportunities include brand investments and innovation, while risks involve declining volumes and cost pressures in a competitive market.
Trailing returns across standard periods
Latest headlines on both assets
Humana is one of the largest private health insurers in the U.S. with a focus on administering Medicare Advantage plans. The firm has built a niche specializing in government-sponsored programs, with nearly all its medical membership stemming from individual and group Medicare Advantage, Medicaid, and the military's Tricare program. The firm is also a leader in stand-alone prescription drug plans for seniors enrolled in traditional fee-for-service Medicare. Humana offers employer-based plans primarily for small businesses along with specialty insurance offerings such as dental, vision, and life. Beyond medical insurance, the company provides other healthcare services, including primary-care services, at-home services, and pharmacy benefit management.
Read more on HUM →Boston Beer is a leader in U.S. high-end malt beverages and adjacent categories, with strong positions in craft beer, hard cider, and hard seltzer. The firm sells an array of flavor variants and package sizes, predominantly centered around four priority brands: Samuel Adams, Angry Orchard, Twisted Tea, and Truly Hard Seltzer. Its drinks are produced in both company-owned breweries as well as through third-party contract arrangements, and while the company primarily goes to market through independent wholesalers (as mandated by law), it operates a fairly large salesforce to induce demand across the value chain (distributors, retailers, and drinkers). The preponderance of revenue is generated domestically.
Read more on SAM →